Heartflow 10-Q: Q3 Revenue $72.9M, Net Loss Narrows to $11.5M, $253M Cash
HTFL has more than doubled off its 52-week low of $20.13 on elevated volume (2.1× avg).
Summary
Heartflow's Q3 10-Q confirms $72.9 million revenue (up 57%) and a narrowed $11.5 million net loss, with $253.0 million in cash and investments. It also newly discloses a DOJ anti-kickback investigation, new patent litigation and fresh 10b5-1 selling plans by three executives.
Key Events · Earnings and Guidance · HTFL
-
Q3 Revenue Jumps 57% to $72.9M
Revenue rose to $72.9 million from $46.3 million a year earlier, driven by an 89% increase in revenue cases to 98,155, partly offset by lower average selling price from a higher mix of clinic-based accounts and higher volume rebates.
-
Net Loss Narrows to $11.5M
The $11.5 million net loss compares with $50.9 million a year earlier, but the prior-year quarter included a $32.1 million non-cash warrant remeasurement charge; operating loss improved to $13.8 million from $15.1 million.
-
Cash of $253.0M Funds 12 Months
Cash, cash equivalents and investments totaled $253.0 million at September 30, 2026, which management says funds planned operating expenses and capital expenditures for at least the next 12 months; nine-month operating cash use was $38.4 million.
-
DOJ Anti-Kickback Investigation Disclosed
The company and certain employees received civil investigative demands from the DOJ in October 2025 under the Anti-Kickback Statute and Civil False Claims Act; the outcome and any financial impact cannot be estimated.
Analysis · HTFL · Industrial Applications And Services
Today's 8-K is now backed by full financials in the 10-Q, which also carries facts the headline release did not. The loss shrank to $11.5 million from $50.9 million a year ago, but that comparison is flattered by a $32.1 million non-cash warrant remeasurement charge in the prior-year quarter; the operating loss actually improved only modestly, to $13.8 million from $15.1 million. Gross margin rose to 84% from 77% on 89% case-volume growth, and the company ended September with $253.0 million in cash and investments, which management says funds at least 12 months of operations. Newly detailed in the filing: a DOJ anti-kickback/False Claims Act investigation, a new patent suit against Elucid filed October 22, 2026, and a California wage-and-hour class action, plus new 10b5-1 selling plans adopted by the CEO, CFO and CMO on September 15, 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HTFL was trading at $54.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $20.13 to $60.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.